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Objectives. This study was designed to determine the effect of 
oral hydralazine on the development of nitrate tolerance in 
patients with chronic congestive heart failure. 
Background. Early development of nitrate tolerance with either 
continuous administration of intravenous or topical nitrate prep- 
arations or frequent dosing of oral nitrates leads to significant 
attenuation of nitrate-mediated hemodynamic and anti.ischemic 
effects. In recent animal experiments, prevention of nitroglycerin- 
induced bemodynamic tolerance with a concomitant use of bydral- 
azine was demonstrated. This finding may have important clinical 
relevance. 
Methods. Twenty.eight patients with chronic heart failure due 
to left ventricular systolic dysfunction were randomized to receive 
either a continuous infusion (24 h) of nitroglycerin alone (group I, 
14 patients) or concomitantly with oral hydralazine (75 mg four 
times a day [group II, 14 patients]). The effect of nitroglycerin in 
each group was evaluated by analysis of variance for repeated 
measures. The power of the analysis to detect a 5.4-ram Hg (20%) 
change in mean pulmonary artery wedge pressure was 90%. 
Results. Baseline hemodynamic variables as well as the initial 
hemodynamic response to nitroglycerin were comparable in both 
groups. Compared with the initial response to nitroglycerin, a
significant attenuation of effect was found in group I at 24 h in 
mean (-+SE) pulmonary artery pressure (27 -+ 4% vs. 10 -+ 3%, 
p < 0.05) and mean pulmonary artery wedge pressure (40 -+ 4% 
vs. 16 -+ 4%, p < 0.05). In group II, conversely, oral hydralazine 
prevented nitroglycerin.induced hemodynamic tolerance and re- 
suited in a persistent effect on mean pulmonary artery and wedge 
pressures throughout he study period (31 ± 3% vs. 27 -+ 4%, p = 
0.13 and 37 --+ 4% vs. 34 -+ 6%, p = 0.40, respectively). In addition, 
the initial effect on blood pressure was attenuated at 24 h in group 
I (5 -+ 2% vs. 12 ± 3%, p < 0.05) but not in group II (15 ± 3% vs. 
17 _+ 2%, p = 0.46). 
Conclusions. In patients with chronic heart failure due to left 
ventricular systolic dysfunction, the concomitant use of oral 
hydralazine prevents early development of nitrate tolerance and 
results in a persistent nitrate-mediated hemodynamic effect on 
systemic and pulmonary artery and left ventricular filling pres- 
sures. These data may support he concurrent use of hydralazine 
in patients with heart failure treated with organic nitrates. 
(J Am Coil Cardiol 1995;26:1575-80) 
Organic nitrates have been widely used in the treatment of 
ischemic heart disease and congestive heart failure (1,2). 
However, the development of early tolerance to the vasodi- 
latory effects of these drugs has substantially limited their 
therapeutic efficacy (3). The exact mechanism of nitrate 
tolerance has remained poorly understood (4). It is there- 
fore not surprising that various strategies proposed for 
prevention of nitrate tolerance, including concomitant ad- 
ministration of sulfhydryl groups (5), angiotensin-converting 
enzyme inhibitors (6) or diuretic drugs (3,7), have not 
proved beneficial in patients with heart failure. Although 
intermittent nitrate therapy, which allows a daily nitrate 
From the Division of Cardiology, Department of Medicine, University uf 
Southern California School of Medicine, I~s Angeles. California. 
Manuscript received January. 25, 1995: revised manuscript received May 1+ 
1995, accepted July 12, 1995. 
Address for corresnondence: Dr. Uri Elkayam. USC School of Medicine. 
Division of Cardiology, 2025 Zonal Avenue. Los Angeles. California ~0033. 
washout interval, has been effective in the prevention of 
nitrate tolerance, this regimen is limited by its inability to 
provide a continuous and uninterrupted therapeutic effect 
(7). In a recent study, Bauer and Fung (8) demonstrated 
prevention of nitrate tolerance with concurrent administra- 
tion of hydralazine in a rat model of congestive heart failure. 
Although the combination of nitrates and hydralazine has 
been shown (9,10) to result in beneficial clinical effects in 
patients with heart failure, there is no information available 
regarding the potential effect of hydralazine on nitrate 
tolerance in humans. Therefore, the present study proposed 
to evaluate the effect of concomitant use of oral hydralazine 
on the early development of nitrate tolerance in patients 
with chronic heart failure. 
Methods  
Study patients. Patients with chronic heart failure due to 
left ventricular systolic dysfunction admitted to the Los Ange- 
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for worsening symptoms were enrolled in the study after 
clinical stabilization. 
Of 33 patients who entered the study, 28 demonstrated a 
hemodynamic response to intravenous nitroglycerin, com- 
pleted the study and were included in the analysis (23 men, 5 
women; mean [+_SE] age 48 _+ 1 years, range 24 to 68). 
Coronary artery disease was diagnosed in 5 patients, but the 
cause of heart failure was unknown in 23, 7 of whom had a 
history of hypertension, and 5 a history of excessive alcohol 
consumption. All patients were in New York Heart Associa- 
tion functional class Ill or IV on admission to the hospital and 
were in stable clinical and hemodynamic condition at the time 
of the study. The diagnosis of left ventricular systolic dysfunc- 
tion was established in each patient by either contrast or 
radionuclide ventriculography (23 patients) or by echocardiog- 
raphy (5 patients). None of the patients had primary valvular 
disease or clinical evidence of myocardial ischemia t the time 
of the study. 
Hemodynamic measurements and computations. Right 
heart catheterization was performed with a balloon-tipped, 
triple-lumen Swan-Ganz catheter. Right atrial, pulmonary 
artery and left ventricular filling pressures, determined indi- 
rectly from the mean pulmonary artery wedge pressure, were 
recorded using an Electronics for Medicine AR-6 recorder; 
mean pressures were obtained by electronic integration. Heart 
rate was determined from electrocardiographic recordings, 
and arterial blood pressure was measured by the standard cuff 
method. Cardiac output was determined by thermodilution, as 
previously described (11). Calculations of mean arterial blood 
pressure, cardiac index, and systemic and pulmonary vascular 
resistance were performed by standard formulas. 
Study protocol. All patients were in stable clinical and 
hemodynamic condition. Vasodilators, other than hydralazine, 
were withheld for at least 24 h before the initiation of the 
study, but the usual doses of digitalis and diuretic drugs were 
continued throughout the study. Patients randomized to oral 
hydralazine therapy received 75 mg four times daily, with the 
first dose given at least 24 h before the study. To allow for any 
spontaneous hemodynamic changes (12) pulmonary artery 
catheters were inserted at least 16 h before the start of the 
study. Hemodynamic stability (<10%. variation in two consec- 
utive measurements) was ensured before the initiation of the 
study by consecutive r adings performed at -30-rain intervals. 
Values obtained at the last measurement were used as baseline 
values. Baseline hemodynamic measurements in the hydrala- 
zine group were initiated -3 h after administration f the last 
hydralazine dose (6 AM). 
After obtaining baseline measurements, an intravenous 
infusion of nitroglycerin regulated by an infusion pump (IVAC 
530) was started at a rate of 20 ~g/min through special 
nitroglycerin polyethylene tubing. The rate of infusion was 
then increased in increments of20 to 60/~g/min every 5 min to 
achieve at least a 30% reduction in mean pulmonary artery 
wedge pressure or until a maximal dose of 560/~g/min was 
reached. In patients who did not respond to the maximal dose 
Table l. Baseline Variables in the Two Study Groups* 
Group II 
Group 1 (NTG + HYD 
(NTG [n - 14]) [n = 14]) 
Age (yr) 48 ± 1 48 - 1 
NTG dose (~,g/min) 215 + 50 185 _+ 33 
EF(%) 22-+ 1 23_+1 
HR (beats/min) 94 ± 4 93 _+ 5 
CI (liters/rain pcr m z) 2.1 ± 0.3 2.3 -+ 0.2 
RA (mm Hg) 13 ± 2 12 _+ 2 
PA (mm Hg) 38 : 3 42 + 3 
PAWP (ram Hg) 27 - 2 27 _+ 2 
SVR (dynes.s.cm 5) 1,786 _+ 227 1,640 _+ 129 
PVR (dynes.s.crn s) 268 ± 53 318 _+ 46 
*No significant differences between groups for any variable. Data presented 
are mean value + SE. CI - cardiac index; EF - ejection fraction; 
HR heart rate: HYD - hydralazioe; NTG - nitroglycerin; PA = pulmonary 
artery pressure; PAWP = pulmonary artery wedge pressure; PVR = pulmonary 
vascular resistance; RA = right atrial pressure; SVR = systemic vascular 
resistance. 
of nitroglycerin, the infusion of the drug was discontinued, and 
these patients were excluded from the study. In those who 
responded to nitroglycerin, the dose required to achieve the 
desired hemodynamic response was maintained at the same 
rate for 24 h, and hemodynamic measurements were repeated 
at 1, 2, 4, 8, 12, 16, 20 and 24 h. 
Statistical analysis. One-way repeated measures of analy- 
sis of variance and the Newman-Keuls test were used to 
evaluate the temporal hemodynamic effect of nitroglycerin in 
each group, as represented by the measured or calculated 
values throughout the study, or the difference in these values 
from baseline. Single comparisons were performed with the 
Student  test. Analyses were performed with the use of the 
CLINFO system and the SAS statistical package on the IBM 
370 system at the University of Southern California. Results 
are expressed as mean value _+ SE; p < 0.05 was considered 
statistically significant. A previous tudy (3) in a similar group 
of patients treated with placebo for 24 h demonstrated spon- 
taneous changes <17% in pulmonary artery wedge pressure. 
The power of analysis of variance to detect a20% (5.4 mm Hg) 
change in pulmonary artery wedge pressure in the present 
study was - 90%. 
Resul ts  
Patients. Twenty-eight patients (14 in each group) demon- 
strated the desired hemodynamic response to nitroglycerin and 
completed the study. Table 1 compares the results in patients 
receiving nitroglycerin alone (group I) with those receiving 
nitroglycerin i  combination with oral hydralazine (group II). 
No significant differences were found between the two groups 
for age (48 _+ 1 years in both groups), left ventricular ejection 
fraction (22 _+ 1% in 11 group I patients, 23 +_ 1% in 12 group 
II patients) or measured or calculated baseline hemodynamic 
values. The dose of nitroglycerin used to achieve the desirable 
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reduction in mean pulmonary artery wedge pressure was 215 ± 
50 ~g/min in the nitroglycerin group and 185 ± 33/~g/min in 
the nitroglycerin plus hydralazine group; this difference was 
not statistically significant. 
Hemodynamic hanges over time. Titration of nitroglyc- 
erin dose to achieve a ->30% reduction in mean pulmonary 
artery wedge pressure resulted in a significant decrease in 
mean right atrial and pulmonary and systemic arterial blood 
pressures and an increase in cardiac index. There was no 
significant change in heart rate (Table 2). Initial changes from 
baseline in all hemodynamic variables, as seen at peak nitro- 
glycerin titration, were similar between the two groups and 
demonstrated no statistically significant difference. Analysis of 
hemodynamic hanges over time revealed the following find- 
ings: mean right atrial pressure decreased by 39 _+ 6% at peak 
nitroglycerin titration (from 13 ± 2 to 9 ± 2 mm Hg) in group 
I and by 46 _+ 8% (from 12 ± 2 to 7 _+ 1 mm Hg) in group II 
(p = 0.17). These hemodynamic changes persisted throughout 
the study in both groups without an indication for attenuation 
of effect (Table 2). At 24 h, mean right atrial pressure was 
reduced by 25 + 7% in group I and by 25 _ 20% in group II 
(p = 0.98), The initial change in cardiac index was also 
preserved in both groups (Table 2). Cardiac index increased by 
35 +_ 10% in group I (from 2.1 ± 0.3 to 2.5 ± 0.2 liter/min per 
m z) and by 29 _+ 13% in group II (from 2.3 ± 0.2 to 2.8 ± 0.2 
liter/rain per m 2) at peak titration and remained augmented at 
24 h (39 +_ 10% and 26 + 9%, respectively). Similarly, systemic 
and pulmonary vascular resistances were reduced by 25 _+ 9% 
and 13 +_ 9% (from 1,786 _+ 227 to 1,164 _+ 96 dynes.s.cm -5 
and from 267 ___ 53 to 192 _ 22 dynes.s.cm -5, respectively) in 
group I and by 25 ± 6% and 39 ± 80% (from 1,640 ± 129 to 
1,188 ± 98 dynes.s.cm 5 and from 318 ± 46 to 182 ± 34 
dynes.s.cm ~) in group I. These changes remained unattenu- 
ated at the end of the study. 
Nitroglycerin titration resulted in a comparable mean arte- 
rial blood pressure reduction in both groups (Table 2), with a 
12 ± 3% reduction in group I (from 84 ± 3 to 73 ± 3 mm Hg) 
and a 17 ± 2% reduction in group II (from 90 _+ 4 to 75 _+ 
4 mm Hg). Unlike the persistent effect on right atrial pressure 
and cardiac index seen for the duration of the study, the effect 
on systemic blood pressure was progressively attenuated in 
group I during the study, with a difference of only 5 ± 2% in 
mean blood pressure from baseline at 24 h (Fig. 1). In contrast, 
the effect on mean blood pressure in group II remained 
unattenuated throughout he study, with a 15 _+ 3% reduction 
still seen at 24 h (p < 0.05 vs. group I). A similar and 
statistically significant difference was found between the two 
groups in the persistence of initial changes in mean pulmonary 
artery and wedge pressures (Figs. 2 and 3). At peak nitroglyc- 
erin titration, mean pulmonary artery pressure (Fig. 2) dem- 
onstrated a similar reduction in both groups (27 ± 4% in group 
I [from 38 ± 3 to 28 ± 2 mm Hg], 31 ± 3% in group II [from 
42 ± 3 to 28 _+ 2 mm Hg]). Although the reduction in mean 
pulmonary, artery pressure persisted for the duration of the 
study in group II (27 ± 4% at 24 h), the change in this 
hemodynamic variable was significantly attenuated in group I, 
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Figure 1. Effect of 24 h of nitroglycerin i fusion alone (NTG; 14 
patients) or in combination with hydralazine (NTG + HYD; 14 
patients) on mean systemic arterial pressure. *p < 0.05 versus 0h. 
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Figure 3. Effect of 24 h of nitroglycerin infusion alone (NTG) or in 
combination with hydralazine (NTG + HYD) on mean pulmonary 
artery wedge pressure. *p < 0.05 versus 0h. 
with a value of only 10 _+ 3% at 24 h (p < 0.01 vs. group II). 
In addition, difference from baseline, as found at 8 and 16 h 
(15 _+ 4% and 15 + 3%, respectively), was significantly smaller 
than the difference found at 0 h (Fig. 2). The initial reduction 
in mean pulmonary artery wedge pressure (Fig. 3) was 40 + 
4% in group I (from 27 + 2 to 17 _+ 1 mm Hg) and 37 + 4% 
in group II (from 27 _+ 2 to 17 _+ 2 mm Hg). This initial change 
in wedge pressure was gradually attenuated in group I, leading 
to a statistically significant increase from the value obtained at 
0 h to that as early as 4 h of nitroglycerin fusion (16 _+ 4% vs. 
40 _+ 4%, p < 0.05). In contrast, an initial reduction in mean 
pulmonary artery wedge pressure was maintained for the 
duration of the study in group 1I and was 34 + 6% at 24 h (p = 
0.40 vs. 0 h, p < 0.05 vs. group 1). 
Discuss ion  
The results of the present investigation are in accordance 
with previous reports (5,13,14) of early development of toler- 
ance to the initial hemodynamic effects of nitroglycerin when 
Figure 2. Effect of 24 h of nitroglycerin i fusion alone (NTG) or in 
combination with hydralazine (NTG + HYD) on mean pulmonary 
artery pressure (14 patients in each group). *p < 0.05 versus values 
obtained at peak nitroglycerin titration (0 h). 
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given as a continuous infusion to patients with heart failure. In 
the present study, a marked attenuation ofnitroglycerin effect 
on systemic and pulmonary arterial pressures and left ventric- 
ular filling pressure occurred when the drug was given alone 
within the first 24 h of therapy. This attenuation is evidenced 
by a statistically significant increase in these pressures com- 
pared with values obtained at peak nitroglycerin titration 
(Table 2, Fig. 1 to 3). Although changes in mean right atrial 
pressure, cardiac index and both systemic and pulmonary 
vascular resistance seemed to remain unattenuated, these 
findings are most likely related to the limited duration of the 
study period. This assumption is supported by the results of 
previous tudies (14) demonstrating a complete loss of effect 
on these parameters within 48 h of continuous nitroglycerin 
infusion. 
Previous attempts to prevent nitrate tolerance. Because of 
the potential role of nitrate tolerance in limiting the therapeu- 
tic effects of these drugs, an extensive ffort has been made in 
recent years by numerous investigators to develop effective 
strategies for the prevention of this phenomenon (3,15). 
Because depletion of tissue sulfhydryl groups has been consid- 
ered a likely mechanism of nitrate tolerance (16), sulfhydryl- 
containing compounds have been used in conjunction with 
organic nitrates to prevent olerance. Although sulfhydryl 
donors, such as N-acetylcysteine and methionine, have been 
reported to reverse nitrate tolerance (14,17) in patients with 
heart failure, the effect was only partial and the administration 
of N-acetylcysteine i  the nontolerant s age failed to prevent 
tolerance development (5). 
Because activation of neurohumoral, vasoconstrictive 
mechanisms has been considered a potential cause of nitrate 
tolerance (3,5,14), angiotensin-converting e zyme inhibitors 
have been used in combination with organic nitrates in an 
attempt o prevent he development of tolerance (18). Al- 
though prolongation of nitrate-mediated hemodynamic a tion 
has been reported with a concomitant administration of 
angiotensin-converting e zyme inhibitors by some investiga- 
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tors (19), others failed to demonstrate prevention of nitrate 
tolerance with the same drugs (6,20). Therefore, more infor- 
mation is needed to determine the clinical role of angiotensin- 
converting enzyme inhibitors in the prevention of nitrate 
tolerance in patients with heart failure. 
An increase in blood volume has been reported (5) in 
patients receiving nitrate therapy and has been suggested (3,5) 
as a mechanism for early attenuation of the hemodynamic 
effects. The concomitant use of diuretic drugs in normal 
volunteers (21) and in patients with ischemic heart disease (22) 
and heart failure (13,23,24) failed to prevent the development 
of nitrate tolerance. 
Interaction between itroglycerin and hydralazine. A re- 
cent study by Bauer and Fung (8) demonstrated a beneficial 
interaction between itroglycerin and hydralazine, with pre- 
vention of nitrate tolerance ina rat model of heart failure. The 
results of the present investigation extend these findings and 
demonstrate a potential role for hydralazine in the prevention 
of nitrate tolerance in patients with heart failure. Unger et al. 
(25) demonstrated in an in vitro experiment a potentiation of
nitroglycerin-induced vasorelaxation with hydralazine in iso- 
lated rat aortas rendered in vivo nitrate tolerant and suggested 
an interaction between hydralazine and pyridoxal as the mech- 
anism responsible for this effect. Pyridoxal has been shown to 
enhance the availability of sulfhydryl groups in vascular 
smooth muscle by inducing a breakdown of sulfhydryl- 
containing amino acids and may thereby potentiate the re- 
sponse to nitroglycerin. However, Bauer and Fung (8) failed to 
demonstrate hydralazine-induced prevention of vascular toler- 
ance to nitroglycerin i  an isolated rat aorta and concluded a 
low likelihood for a cellular interaction between the two drugs. 
Nitrate administration has been shown to decrease renal 
blood flow in both animals and humans with heart failure 
(26,27). This change in renal perfusion may be responsible for 
neurohumoral ctivation (5,14), a possible mechanism of ni- 
trate tolerance (3). In contrast, the administration f hydrala- 
zinc was found to cause a significant increase in renal blood 
flow in patients with heart failure (26,28). On the basis of these 
findings, Bauer and Fung (8) suggested a prevention of the 
nitrate-mediated decrease in renal blood flow and neurohor- 
monal stimulation with hydralazine as a possible explanation 
for prevention of nitrate tolerance. However, further investi- 
gations will be needed to evaluate the validity of this potential 
mechanism of nitrate-hydralazine teraction i  patients with 
chronic heart failure. 
Hydralazine has been shown to exert a hemodynamic effect 
in patients with chronic heart failure (29-35). it could there- 
fore be argued that the persistent hemodynamie effect in 
patients receiving nitrates plus hydralazine may reflect a 
beneficial hemodynamic effect of hydralazine despite the de- 
velopment of nitrate tolerance. However, this argument isnot 
supported by the results of the present and previous tudies. 
Lack of difference in hemodynamic response to nitroglycerin 
both groups uggests only a small or no hemodynamic effect of 
hydralazine in our patients. This suggestion is further sup- 
ported by a previously published report (29) demonstrating 
failure to show hemodynamic response to 75 mg of oral 
hydralazine (dose used in the present study) in 41 of 45 
patients with chronic heart failure. In addition, a persistent, 
substantial reduction in left ventricular filling pressure is 
unlikely to be due to hydralazine. This drug has a predominant 
effect on the arteriolar circulation and has demonstrated only 
a small and often insignificant effect on left ventricular filling 
pressure (30-35). 
Summary. The results of the present investigation demon- 
strate prevention of early attenuation of nitroglycerin- 
mediated effects on systemic and pulmonary artery pressures 
and left ventricular filling pressure with the concomitant 
administration of oral hydralazine in patients with chronic 
congestive heart failure. Our results support a recently pub- 
lished study reporting prevention of nitrate tolerance with 
concurrent use of hydralazine in an animal model of heart 
failure. Although the mechanism for the favorable interaction 
between hydralazine and organic nitrates remains unclear, our 
findings may provide an explanation for the beneficial effect of 
isosorbide dinitrate when used in combination with hydrala- 
zinc, on left ventricular function, exercise capacity and survival 
in patients with chronic heart failure, as demonstrated in the 
Veterans Heart Failure Trials (V-HeFT) (9,10). The results of 
the present study may indicate arationale for the concomitant 
use of hydralazine in patients with heart failure receiving 
nitrate therapy. 
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